Share

November 2019; 6 (6) ArticleOpen Access

Effects of natalizumab therapy on intrathecal antiviral antibody responses in MS

Fabienne Largey, Ivan Jelcic, Mireia Sospedra, Christoph Heesen, Roland Martin, Ilijas Jelcic
First published September 25, 2019, DOI: https://doi.org/10.1212/NXI.0000000000000621
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
852

Share

Article Information

vol. 6 no. 6 e621
DOI: 
https://doi.org/10.1212/NXI.0000000000000621
PubMed: 
31554671
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Online ISSN: 
2332-7812
History: 
  • Received August 15, 2018
  • Accepted in final form July 31, 2019
  • First Published September 25, 2019.
Copyright & Usage: 
Copyright © 2019 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Author Disclosures

    1. Fabienne Largey, PhD,
    2. Ivan Jelcic, PhD,
    3. Mireia Sospedra, PhD,
    4. Christoph Heesen, MD,
    5. Roland Martin, MD and
    6. Ilijas Jelcic, MD
  1. Fabienne Largey, PhD,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. Celgene GmbH, Medical Affairs, 2 years (employment started after end of study)

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Ivan Jelcic, PhD,
    3. Scientific Advisory Boards:

    1. Dr. Ivan Jelcic received compensation for serving on a scientific advisory board by Sanofi Genzyme in 2018.

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Dr. Ivan Jelcic received speaker honoraria from the Swiss Society of Multiple Sclerosis (non-profit) in 2018.

    Editorial Boards:

    1. NONE

    Patents:

    1. Dr. Ivan Jelcic is listed as inventor on a patent of human monoclonal antibodies against JCPyV VP1 for the treatment of PML.

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Mireia Sospedra, PhD,
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Invited editor of the special issue `Understanding and Elucidation of the Specificity of αβ-T cells`in Frontiers in Immunology

    Patents:

    1. Sospedra, M., Martin, R., Planas, R., Jelcic, I., Santos, R., Pinilla, C. IMMUNODOMINANT PROTEINS AND FRAGMENTS IN AUTOIMMUNE DISEASES. EP18180326.3 (2018). Jelcic, I., Martin, R., Schippling, S., Sospedra, M., Yousef, S. POLYOMA VIRUS JC PEPTIDES AND PROTEINS IN VACCINATION AND DIAGNOSTIC APPLICATIONS WO Patent 2,013,014,134 (2013)

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Christoph Heesen, MD,
    5. Scientific Advisory Boards:

    1. Ibsen Pharmaceuticals

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Received speaker honoraries from Biogen, Merck, Genzyme, Novartis

    Editorial Boards:

    1. International Journal of MS Care, 2014 until now

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other activities:

    1. Received Research grants from Genzyme, Biogen, Roche, Novartis, Merck, Roche.

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Genzyme Sanofi Aventis Biogen Novartis Merck Roche

    Research Support, Government Entities:

    1. German Minstery of Research, PI 2012-2016 Hertie Foundation, PI 2014-2016 German Innovation Fond, PI 2018-2021

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NMSS

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Roland Martin, MD and
    6. Scientific Advisory Boards:

    1. I have received personal compensation for advisory work to Biogen, Merck & Serono, Teva, Genzyme Sanofi-Aventis, CellProtect, Neuway

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. I have received personal compensation/honoraria for speaking at workshops or small meetings by Biogen and Merck & Serono, Novartis, Roche, Genzyme, Teva, Sanofi-Aventis.

    Editorial Boards:

    1. NONE

    Patents:

    1. Together with B. Bielekova, H. McFarland and T. Waldmann I am a coholder of a patent claiming the therapeutic efficacy of anti-CD25 monoclonal antibody treatment in combination with IFN-b in MS. This patent is owned by NIH, but the patent holders receive periodic royalties. I have received royalties in the last five years. I am also inventor or co-inventor on University Zurich-held patents in the context of antigen-specific tolerization with peptide-coupled cells.

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. I have been consulting for the Myelin Repair Foundation, The Weatherall Institute for Molecular Studies, University of Oxford, the German Research Society, and the Hertie Foundation. These are all non-profit academic or private institutions, foundations. I am a member of the Kuratorium of the Jung Foundation for Science, Hamburg, Germany, also a non-profit organization; the Swiss Multiple Sclerosis Society, also non-profit, and several other national MS societies, in each case non-profit.

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Novartis has given us financial support (unrestricted grant) to examine the effects of fingolimod on immune responses against herpes viruses. Biogen has given us financial support (unrestricted grant) to study the effects of natalizumab on the intrathecal antibody response in MS. We have also received unrestricted support for the department of neuroimmunology and MS research from Roche.

    Research Support, Government Entities:

    1. Swiss National Science Foundation (throughout last 7 years). European Union Seventh Framework Program. European Research Council Advanced Grant. Clinical Research Priority Program Multiple Sclerosis of the University Zurich for the last 6 years.

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. I hold stock of CellProtect, a small biotech Company.

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. I had received royalty payments (periodically) from a NIH- Held patent on the use of anti-CD25 (daclizumab) in multiple sclerosis.

    Stock/Stock Options, Research Sponsor:

    1. I am Co-Founder and Co-Owner of Cellerys, a startup company out of Univ. Zurich, which is pursuing antigen-specific tolerization.

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. Ilijas Jelcic, MD
    7. Scientific Advisory Boards:

    1. Neuway, Merck, Novartis and Sanofi Genzyme

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Novartis, speaker honoraria

    Editorial Boards:

    1. NONE

    Patents:

    1. Ivan J. and R.M. are listed as inventors on a patent of the human monoclonal antibodies against JCPyV VP1 for the treatment of PML. R.M., Ilijas J. and M.S. are listed as coinventors on a patent on vaccination against PML by immunisation with JCPyV VP1 protein.

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Novartis, unrestricted grant; Biogen, unrestricted grant (Biogen is the maker of Natalizumab, and has not imposed and has not tried to impose any restrictions on our submission of this work)

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Neuroimmunology and Multiple Sclerosis Research Section (F.L., Ivan Jelcic, M.S., R.M., Ilijas Jelcic), Department of Neurology, University Hospital of Zurich, Switzerland; and Institute for Neuroimmunology and Multiple Sclerosis (inims) (C.H.), Center for Molecular Neurobiology (ZMNH), University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  1. Correspondence
    Dr. Ilijas Jelcic Ilijas.Jelcic{at}usz.ch

Article usage

Article usage: September 2019 to October 2023

AbstractFullPdfSource
Sep 20191112437Highwire
Oct 20191044177Highwire
Nov 20199027976Highwire
Dec 201989735Highwire
Jan 202022528Highwire
Feb 202026920Highwire
Mar 202044222Highwire
Apr 202036321Highwire
May 202068315Highwire
Jun 202097313Highwire
Jul 202013010Highwire
Aug 202043615Highwire
Sep 20203487Highwire
Oct 202006738Highwire
Nov 202015215Highwire
Dec 202044810Highwire
Jan 202122113Highwire
Feb 202101817Highwire
Mar 202172618Highwire
Apr 202132510Highwire
May 20213295Highwire
Jun 202122611Highwire
Jul 202128113Highwire
Aug 202105314Highwire
Sep 202162713Highwire
Oct 202145028Highwire
Nov 202112527Highwire
Dec 202123114Highwire
Jan 202213012Highwire
Feb 202222710Highwire
Mar 202213012Highwire
Apr 202211620Highwire
May 202252825Highwire
Jun 20221126Highwire
Jul 20223152Highwire
Aug 20227323Highwire
Sep 202284016Highwire
Oct 202263814Highwire
Nov 2022196728Highwire
Dec 202212612Highwire
Jan 202311378Highwire
Feb 202333110Highwire
Mar 20232489Highwire
Apr 202382115Highwire
May 20239169Highwire
Jun 2023102210Highwire
Jul 20239109Highwire
Aug 202318179Highwire
Sep 202312166Highwire
Oct 20238115Highwire

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. [email protected]
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

  • No related articles found.

Topics Discussed

Alert Me

Recommended articles